Actualizado 31/03/2008 19:18
- Comunicado -

Landmark Trial ONTARGET(R) Proves Telmisartan is as Protective as Ramipril and Better Tolerated in a Broad High-Risk Car

Contact: Corporate Division Communications, Boehringer Ingelheim GmbH, 55216 Ingelheim/Germany, Phone: +49-6132-77-97296, 77-8271, Fax: +49-6132-72-6601, E-mail: press@boehringer-ingelheim.com

Contenido patrocinado